Mahsa Keshavarz-Fathi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mahsa Keshavarz-Fathi has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Nima Rezaei
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Tehran University of Medical Sciences Tehran Iran
22 shared publications Nima Rezaei
Tehran University of Medical Sciences
10 shared publicationsSepideh Razi
Universal Scientific Education and Research Network (USERN)
5 shared publicationsArmin Hirbod-Mobarakeh
Border of Immune Tolerance Education and Research Network (BITERN), Universal Scientific Education and Research Network (USERN), Tehran, Iran
2 shared publicationsMahsa Eskian
Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
2 shared publicationsNeda Khalili
Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 1 May 2025
- Published by National Academy of Sciences of Tajikistan
- Vol. 29 (3) , 159-166
Upregulation of CircCSPP1, CircNRIP1, and CircSMAD2 in Breast Cancer and Their Potential as Diagnostic Biomarkers
Background: Identifying novel diagnostic biomarkers with stable structures, such as circulating circular RNAs (circRNAs) can improve the early detection and management of BC. Herein, we conducted this study to analyze the expression profile of four circRNAs, including circCSPP1 (hsa_circ_0001806), circNRIP1 (hsa_circ_0004771), circSMAD2 (hsa_circ_0000847), and circFOXP1 (hsa_circ_0008234) in BC. Methods: Tumor ...
- 1 May 2025
- Published by National Academy of Sciences of Tajikistan
- Vol. 29 (3) , 159-166
Open AccessUpregulation of CircCSPP1, CircNRIP1, and CircSMAD2 in Breast Cancer and Their Potential as Diagnostic Biomarkers
Background: Identifying novel diagnostic biomarkers with stable structures, such as circulating circular RNAs (circRNAs) can improve the early detection and management of BC. Herein, we conducted this study to analyze the expression profile of four circRNAs, including circCSPP1 (hsa_circ_0001806), circNRIP1 (hsa_circ_0004771), circSMAD2 (hsa_circ_0000847), and circFOXP1 (hsa_circ_0008234) in BC. Methods: Tumor ...
- Open Access
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
Bilateral localized bullous pemphigoid in a young adult patient: A case report
Bullous pemphigoid is the most common autoimmune subepidermal blistering disease, which typically presents in the elderly. Localized bullous pemphigoid is a rare variant of bullous pemphigoid, with only about 100 cases reported up to date. In this report, we describe a 32-year-old healthy male patient with bilateral hemorrhagic bullae and erosive lesions limited to the lower extremities. A biopsy for hematoxylin and eosin stain and direct immunofluorescence established the diagnosis of bullous pemphigoid. The blistering responded well to oral and topical steroids. The exact etiology of this rare variant of bullous pemphigoid remains unknown, leading to ongoing debates and numerous suggested hypotheses.
- 1 January 2023
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 11
Open AccessBilateral localized bullous pemphigoid in a young adult patient: A case report
Bullous pemphigoid is the most common autoimmune subepidermal blistering disease, which typically presents in the elderly. Localized bullous pemphigoid is a rare variant of bullous pemphigoid, with only about 100 cases reported up to date. In this report, we describe a 32-year-old healthy male patient with bilateral hemorrhagic bullae and erosive lesions limited to the lower extremities. A biopsy for hematoxylin and eosin stain and direct immunofluorescence established the diagnosis of bullous pemphigoid. The blistering responded well to oral and topical steroids. The exact etiology of this rare variant of bullous pemphigoid remains unknown, leading to ongoing debates and numerous suggested hypotheses.
- 11 May 2021
- Published by Springer Nature
- Vol. 1318, 575-604
Prevention of COVID-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions
The disease 2019 (COVID-19) made a public health emergency in early 2020. Despite attempts for the development of therapeutic modalities, there is no effective treatment yet. Therefore, preventive measures in various settings could help reduce the burden of disease. In this chapter, the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19, non-pharmaceutical approaches at individual and population level, chemoprevention, immunoprevention, preventive measures in different healthcare settings and other professions, special considerations in high-risk groups, and the role of organizations to hamper the psychosocial effects will be discussed.
- 11 May 2021
- Published by Springer Nature
- Vol. 1318, 575-604
Prevention of COVID-19: Preventive Strategies for General Population, Healthcare Setting, and Various Professions
The disease 2019 (COVID-19) made a public health emergency in early 2020. Despite attempts for the development of therapeutic modalities, there is no effective treatment yet. Therefore, preventive measures in various settings could help reduce the burden of disease. In this chapter, the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19, non-pharmaceutical approaches at individual and population level, chemoprevention, immunoprevention, preventive measures in different healthcare settings and other professions, special considerations in high-risk groups, and the role of organizations to hamper the psychosocial effects will be discussed.
- 27 February 2021
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 69 (1) , 1-19
Cancer Immunoprevention: Current Status and Future Directions
Cancer is one of the most serious diseases affecting health and the second leading cause of death worldwide. Despite the development of various therapeutic modalities to deal with cancer, limited improvement in overall survival of patients has been yielded. Since there is no certain cure for cancer, detection of premalignant lesions, and prevention of their progression are vital to the decline of high morbidity and mortality of cancer. Among approaches to cancer prevention, immunoprevention has gained further attention in recent years. Deep understanding of the tumor/immune system interplay and successful prevention of virally-induced malignancies by vaccines have paved the way toward broadening cancer immunoprevention application. The identification of tumor antigens in premalignant lesions was the turning point in cancer immunoprevention that led to designing preventive vaccines for various malignancies including multiple myeloma, colorectal, and breast cancer. In addition to vaccines, immune checkpoint inhibitors are also being tested for the prevention of oral squamous cell carcinoma (SCC), and imiquimod which is an established drug for the prevention of skin SCC, is a non-specific immunomodulator. Herein, to provide a bench-to-bedside understanding of cancer immunoprevention, we will review the role of the immune system in suppression and promotion of tumors, immunoprevention of virally-induced cancers, identification of tumor antigens in premalignant lesions, and clinical advances of cancer immunoprevention.
- 27 February 2021
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 69 (1) , 1-19
Cancer Immunoprevention: Current Status and Future Directions
Cancer is one of the most serious diseases affecting health and the second leading cause of death worldwide. Despite the development of various therapeutic modalities to deal with cancer, limited improvement in overall survival of patients has been yielded. Since there is no certain cure for cancer, detection of premalignant lesions, and prevention of their progression are vital to the decline of high morbidity and mortality of cancer. Among approaches to cancer prevention, immunoprevention has gained further attention in recent years. Deep understanding of the tumor/immune system interplay and successful prevention of virally-induced malignancies by vaccines have paved the way toward broadening cancer immunoprevention application. The identification of tumor antigens in premalignant lesions was the turning point in cancer immunoprevention that led to designing preventive vaccines for various malignancies including multiple myeloma, colorectal, and breast cancer. In addition to vaccines, immune checkpoint inhibitors are also being tested for the prevention of oral squamous cell carcinoma (SCC), and imiquimod which is an established drug for the prevention of skin SCC, is a non-specific immunomodulator. Herein, to provide a bench-to-bedside understanding of cancer immunoprevention, we will review the role of the immune system in suppression and promotion of tumors, immunoprevention of virally-induced cancers, identification of tumor antigens in premalignant lesions, and clinical advances of cancer immunoprevention.
- Open Access
- 22 February 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-15
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.
- 22 February 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-15
Open AccessCurrent and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint blockade through targeting programmed cell death protein-1 (PD-1) has demonstrated promising antitumor effects in cancer immunotherapy of many different solid and hematologic malignancies. However, despite promising results, a favorable response is observed only in a fraction of patients, and there is still lack of a single therapy modality with curative ability. In this paper, we review the current and future perspectives of PD-1/L1 blockade in cancer immunotherapy, with a particular focus on predictive biomarkers of response to therapy. We also discuss the adverse events associated with PD-1/L1/2 inhibitors, ranging from severe life-threatening conditions such as autoimmune myocarditis to mild and moderate reactions such as skin rashes, and explore the potential strategies for improving the efficacy of immunotherapy with PD-1/L1 checkpoint inhibitors.
- 31 January 2021
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 17 (3) , 209-223
Chimeric antigen receptor T-cell therapy for melanoma
In recent years, chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment. After initial therapeutic success for hematologic malignancies, this approach has been extended fo...
- 31 January 2021
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 17 (3) , 209-223
Chimeric antigen receptor T-cell therapy for melanoma
In recent years, chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment. After initial therapeutic success for hematologic malignancies, this approach has been extended fo...
- 13 December 2020
- Published by Springer Nature
- p. 541-555
Immunopathology and Immunotherapy for Breast Cancer
- 13 December 2020
- Published by Springer Nature
- p. 541-555
Immunopathology and Immunotherapy for Breast Cancer
- 17 August 2020
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 22 (1) , 113-116
Extensive Deep Tissue Involvement in Nicolau Syndrome and Below-Knee Amputation: A Case Report and Literature Review
Nicolau syndrome (NS) is a rare cutaneous drug reaction in response to injections administered via any route. Based on the available studies in the medical literature, NS presents as skin and subcutaneous fat necrosis, and typically, it does not cause severe complications such as acute limb ischemia or death. In this study, we report the case of a 6-year-old boy who received an intramuscular injection of benzathine penicillin G for the treatment of bacterial pharyngitis, and subsequently developed a severe case of NS, which eventually led to below-knee amputation of the right lower limb. Although a few approaches have been suggested for the management of NS, they might not be effective under certain circumstances. Early detection, close monitoring, and consistent interventions, such as surgical fasciotomy and debridement procedures, might be necessary in severe cases of NS.
- 17 August 2020
- Published by SAGE Publications in The International Journal of Lower Extremity Wounds
- Vol. 22 (1) , 113-116
Extensive Deep Tissue Involvement in Nicolau Syndrome and Below-Knee Amputation: A Case Report and Literature Review
Nicolau syndrome (NS) is a rare cutaneous drug reaction in response to injections administered via any route. Based on the available studies in the medical literature, NS presents as skin and subcutaneous fat necrosis, and typically, it does not cause severe complications such as acute limb ischemia or death. In this study, we report the case of a 6-year-old boy who received an intramuscular injection of benzathine penicillin G for the treatment of bacterial pharyngitis, and subsequently developed a severe case of NS, which eventually led to below-knee amputation of the right lower limb. Although a few approaches have been suggested for the management of NS, they might not be effective under certain circumstances. Early detection, close monitoring, and consistent interventions, such as surgical fasciotomy and debridement procedures, might be necessary in severe cases of NS.
- 19 May 2020
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 41 (1) , 58-67
DNA Methylation of CD70 Promoter in Juvenile Systemic Lupus Erythematosus
Epigenetic alterations in pathogenesis of systemic lupus erythematosus (SLE) have gained more attention recently in adults. We assessed the methylation of CD70 promoter, a costimulatory molecule on...
- 19 May 2020
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 41 (1) , 58-67
DNA Methylation of CD70 Promoter in Juvenile Systemic Lupus Erythematosus
Epigenetic alterations in pathogenesis of systemic lupus erythematosus (SLE) have gained more attention recently in adults. We assessed the methylation of CD70 promoter, a costimulatory molecule on...